Table 1

Baseline characteristics of all patientsa
Early remission Arm 1 Arm 2 OP group
Baseline characteristics (N= 387) (N= 83) (N= 78) (N= 50)
Mean age (±SD), years 52 ± 14 48 ± 14 51 ± 14 54 ± 14
Females, n (%) 239 (62) 63 (76) 64 (82) 42 (84)
Symptom duration, weeks 17 (9 to 30) 22 (9 to 40) 21 (8 to 29) 18 (9 to 42)
ACPA-positive, n (%) 225 (58) 40 (48) 36 (46) 25 (50)
RA2010, n (%) 297 (77) 66 (80) 64 (82) 40 (80)
Erosive disease, n (%) 63 (16) 10 (12) 13 (17) 3 (6)
DAS, mean ± SD 3.0 ± 0.9 3.6 ± 0.9 3.6 ± 1.0 3.6 ± 0.9
Tender joint count, median (IQR) 5 (2 to 9) 6 (3 to 10) 8 (4 to 12) 7 (3 to 13)
Swollen joint count, median (IQR) 5 (3 to 8) 8 (6 to 13) 9 (6 to 13) 8 (6 to 14)
HAQ, mean ± SD 1.0 ± 0.7 1.4 ± 0.6 1.4 ± 0.65 1.3 ± 0.7
MCS, mean ± SD 51.2 ± 10.2 46.1 ± 12.4 48.8 ± 11.5 46.5 ± 13.3
PCS, mean ± SD 37.6 ± 9.3 33.0 ± 8.8 32.9 ± 8.9 35.2 ± 8.5
Mean MACTAR, mean ± SD 50.1 ± 4.5 47.7 ± 4.6 48.1 ± 4.6 47.7 ± 5.2
Mean VASgl (±SD), mm 43 ± 24 54 ± 20 54 ± 22 51 ± 22
Mean VASda activity (±SD), mm 56 ± 25 66 ± 19 67 ± 22 66 ± 20
Mean VASpain (±SD), mm 50 ± 24 63 ± 19 61 ± 20 60 ± 24
Mean VASms (±SD), mm 56 ± 27 69 ± 21 62 ± 25 54 ± 30

aData are presented as mean ± SD, median (IQR or number (%). ACPA: anticitrullinated protein antibody; DAS: Disease Activity Score; HAQ: Health Assessment Questionnaire; MACTAR: McMaster Toronto Arthritis Patient Preference Questionnaire; MCS: Mental Component Score on the 36-Item Short Form Health Survey; OP group: outside protocol subgroup; PSC: Physical Component Score on the 36-Item Short Form Health Survey; RA2010: rheumatoid arthritis according to the 2010 American College of Rheumatology and European League against Rheumatism classification criteria [4]; VASda: disease activity; VASgl: global health; VASms: morning stiffness; VASpain: pain.

Heimans et al.

Heimans et al. Arthritis Research & Therapy 2013 15:R173   doi:10.1186/ar4361

Open Data